Literature DB >> 10998672

Developing Techniques and Strategies for the Management of Cancer Pain.

.   

Abstract

The past 20 years have seen a great surge of interest in understanding and treating pain. The introduction of sustained-release opioid delivery systems has tremendously advanced our ability to provide improved pain control. Parenteral opioid delivery systems, although available in many developed nations, remain expensive and cumbersome. New advances in parenteral sustained-release systems are currently in development. These advances include liposomal opioid preparations for intrathecal use, transcutaneous patient-controlled delivery, and implantable diffusion reservoirs. Even more exciting are new developments in tissue engineering that may allow the transplantation of human or animal cells, capable of producing natural analgesic substances, into the vicinity of the spinal cord.

Entities:  

Year:  1999        PMID: 10998672     DOI: 10.1007/s11916-999-0011-3

Source DB:  PubMed          Journal:  Curr Rev Pain        ISSN: 1069-5850


  11 in total

1.  Transplantation of human chromaffin cells for control of intractable cancer pain.

Authors:  Y Lazorthes; J C Bès; J Sagen; M Tafani; J Tkaczuk; B Sallerin; I Nahri; J C Verdié; E Ohayon; C Caratero
Journal:  Acta Neurochir Suppl       Date:  1995

2.  Sustained-release morphine for epidural analgesia in rats.

Authors:  T Kim; S Murdande; A Gruber; S Kim
Journal:  Anesthesiology       Date:  1996-08       Impact factor: 7.892

3.  Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience.

Authors:  E Buchser; M Goddard; B Heyd; J M Joseph; J Favre; N de Tribolet; M Lysaght; P Aebischer
Journal:  Anesthesiology       Date:  1996-11       Impact factor: 7.892

4.  Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity.

Authors:  S Lemaire; V K Shukla; C Rogers; I H Ibrahim; C Lapierre; P Parent; M Dumont
Journal:  Eur J Pharmacol       Date:  1993-05-15       Impact factor: 4.432

5.  In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain.

Authors:  G J Lesser; S A Grossman; K W Leong; H Lo; S Eller
Journal:  Pain       Date:  1996 May-Jun       Impact factor: 6.961

6.  Subarachnoid adrenal medullary transplants for terminal cancer pain. A report of preliminary studies.

Authors:  A P Winnie; G D Pappas; T K Das Gupta; H Wang; J D Ortega; J Sagen
Journal:  Anesthesiology       Date:  1993-10       Impact factor: 7.892

7.  Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

Authors:  S Kim; E Chatelut; J C Kim; S B Howell; C Cates; P A Kormanik; M C Chamberlain
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

8.  Chromaffin cell transplants for alleviation of chronic pain.

Authors:  J Sagen
Journal:  ASAIO J       Date:  1992 Jan-Mar       Impact factor: 2.872

9.  Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.

Authors:  Barbara Donner; Michael Zenz; Michael Tryba; Michael Strumpf
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

10.  In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects.

Authors:  S Thysman; V Préat
Journal:  Anesth Analg       Date:  1993-07       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.